Aceragen Incis A Clinical Stage Biopharmaceutical Company Based In Extonpennsylvaniawith A Focus On Developing Therapeutic Drug Candidates For Rare And Orphan Diseasesthe Companywhich Was Formerly Known As Idera Pharmaceuticals Inc Was Incorporated In 1989 And Rebranded In January 2023 Aceragen S Clinical Development Pipeline Includes Acg 701Currently In Phase 2 Trials For Cystic Fibrosis Pulmonary Exacerbations And Melioidosisand Acg 801An Experimental Enzyme Replacement Therapy For Farber Diseasethe Company Also Collaborates With Scriptr Globalincto Develop Gene Therapy Candidates For Myotonic Dystrophy Type 1 And Friedreichae S Ataxia
